AC Immune (NASDAQ:ACIU) Receives Buy Rating from BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by BTIG Research in a report issued on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 197.40% from the company’s current price.

Several other research firms also recently weighed in on ACIU. HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Monday, August 24th. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

AC Immune Stock Performance

NASDAQ:ACIU traded down $0.14 during mid-day trading on Wednesday, hitting $2.69. 214,935 shares of the company traded hands, compared to its average volume of 274,540. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. AC Immune has a one year low of $2.10 and a one year high of $4.00. The stock’s fifty day moving average price is $2.55 and its 200-day moving average price is $2.68. The firm has a market cap of $273.76 million, a price-to-earnings ratio of -5.00 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last released its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $9.59 million. Research analysts anticipate that AC Immune will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

Hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership raised its position in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after buying an additional 30,035 shares in the last quarter. AXQ Capital LP purchased a new stake in shares of AC Immune during the 2nd quarter valued at about $25,000. Finally, Dimensional Fund Advisors LP raised its position in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after buying an additional 176,701 shares in the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting AC Immune

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Part 1 of the VacSYn Phase 2 trial met all primary safety and immunogenicity endpoints through week 100. ACI-7104 was generally safe and well tolerated, produced a 100% antibody response after three immunizations, and showed antibody penetration into cerebrospinal fluid along with signals of target engagement. AC Immune Phase 2 trial announcement
• Positive Sentiment: The results strengthen investor confidence in AC Immune’s approach to targeting alpha-synuclein, a protein associated with Parkinson’s disease, and provide support for advancing ACI-7104 toward later-stage development. AC Immune durable immunogenicity report
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set an $8 price target, while H.C. Wainwright maintained its Buy rating and $12 target. The targets imply substantial upside from the stock’s recent trading level and signal continued analyst optimism. H.C. Wainwright AC Immune rating
• Neutral Sentiment: Part 1 primarily evaluated safety and immune response. Part 2 is intended to assess clinical activity and determine whether ACI-7104 should advance to Phase 3; discussions with the FDA are expected in early 2027. AC Immune Parkinson’s vaccine results
• Negative Sentiment: Despite the favorable data and analyst support, the stock is trading lower, suggesting investors may be taking profits after the initial trial-driven rally or waiting for evidence of meaningful clinical benefit. The absence of Phase 2 efficacy results remains a key risk.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.